New drug combinations and targeted therapies show promise in diabetes and weight loss, while vaccine advances and musculoskeletal benefits emerge from GLP-1 medications

CagriSema, a novel combination therapy, demonstrates superior weight loss and A1c improvements in type 2 diabetes patients compared to either drug alone, with no increased side effects.

Oral GLP-1 drug orforglipron shows positive Phase 3 trial results for glycemic control and weight loss in type 2 diabetes, though with slightly lower tolerability compared to dapagliflozin and oral semaglutide.

GLP-1 medications are linked to additional musculoskeletal benefits including decreased risk for osteoporosis, fractures, disk degeneration, and osteoarthritis in adults with obesity.

Golimumab therapy achieves meaningful disease improvement in more than half of patients with treatment-refractory hidradenitis suppurativa, offering a new option for this difficult-to-treat condition.

High-dose influenza vaccine provides better protection against serious hospitalization outcomes in adults aged 65 and older compared to standard-dose flu shots, according to a meta-analysis.

The NHS in England now offers high-precision targeted radiotherapy for eligible men with early prostate cancer, expanding treatment options in the public healthcare system.

Feeding difficulties in pediatric patients directly correlate with longer hospital stays and higher medical costs, independent of other clinical factors.

Physicians report experiencing moral harm when patients cannot afford necessary medical care, highlighting the psychological burden on healthcare providers amid growing patient debt issues.